Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Neoplasms, Plasma Cell”

4,369 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 4,369 results

Testing effectiveness (Phase 2)Looking for participantsNCT06052826
What this trial is testing

Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study

Who this might be right for
B-Cell Non-Hodgkin LymphomaMultiple Myeloma
City of Hope Medical Center 164
Testing effectiveness (Phase 2)Study completedNCT05968846
What this trial is testing

Repeat PET/CT Imaging of Patients With Amyloid 124I-AT-01 to Measure Changes in Organ-specific Amyloid Load

Who this might be right for
Systemic Amyloidosis
University of Tennessee Graduate School of Medicine 19
Testing effectiveness (Phase 2)Ended earlyNCT01453088
What this trial is testing

Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older

Who this might be right for
Multiple Myeloma
Hackensack Meridian Health 63
Large-scale testing (Phase 3)Looking for participantsNCT05243797
What this trial is testing

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Who this might be right for
Multiple Myeloma
European Myeloma Network B.V. 1,594
Testing effectiveness (Phase 2)Study completedNCT00091260
What this trial is testing

CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis

Who this might be right for
Multiple Myeloma
Vaishali Sanchorawala 82
Not applicableUnknownNCT01891123
What this trial is testing

Explore the Individual Treatment of Docetaxel and Paclitaxel in NSCLC, NPC and BRC by PK-guided Dosing Strategy

Who this might be right for
Non-small Cell Lung CancerBreast CancerNasal Cancer
Sun Yat-sen University 300
Testing effectiveness (Phase 2)Ended earlyNCT00275262
What this trial is testing

Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow Transplantation

Who this might be right for
Hodgkin DiseaseLymphoma, Non-HodgkinMultiple Myeloma+1 more
Abbott 25
Large-scale testing (Phase 3)Study completedNCT02312258
What this trial is testing

Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)

Who this might be right for
Multiple Myeloma
Takeda 706
Not applicableUnknownNCT06258096
What this trial is testing

LI-TASTE Study: Light for Taste

Who this might be right for
Multiple Myeloma
Academic Centre for Dentistry in Amsterdam 52
Not applicableLooking for participantsNCT07260370
What this trial is testing

The Difference of microRNA and Circulating Tumor Cells in Blood Among Cancer Patients With Immunotherapy

Who this might be right for
microRNACirculating Tumor CellsImmunotherapy
Chang Gung Memorial Hospital 300
Early research (Phase 1)WithdrawnNCT02658396
What this trial is testing

GO-203-2C + Bortezomib For Relapsed Or Refractory MM

Who this might be right for
Multiple MyelomaMultiple Myeloma in RelapseRefractory Multiple Myeloma
Dana-Farber Cancer Institute
Not applicableNot Yet RecruitingNCT06330896
What this trial is testing

Disease Characteristics and Treatment Response in Plasma Cell Disorders Patients Based on Genetic Abnormalities From Fluorescence In Situ Hybridization and Next Generation Sequencing

Who this might be right for
Plasma Cell Disorder
Siriraj Hospital 498
Not applicableActive Not RecruitingNCT00039676
What this trial is testing

Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer

Who this might be right for
Waldenstrom MacroglobulinemiaChronic Lymphocytic LeukemiaHodgkin Disease+2 more
National Cancer Institute (NCI) 1,836
Testing effectiveness (Phase 2)Study completedNCT01421186
What this trial is testing

A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
MorphoSys AG 91
Testing effectiveness (Phase 2)Study completedNCT00281476
What this trial is testing

The Effect of High Dose Simvastatine on Multiple Myeloma

Who this might be right for
Multiple Myeloma
Vejle Hospital 10
Not applicableStudy completedNCT01241396
What this trial is testing

Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure

Who this might be right for
Multiple Myeloma
Janssen Pharmaceutica N.V., Belgium 2,396
Large-scale testing (Phase 3)Ended earlyNCT01002248
What this trial is testing

Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients

Who this might be right for
Multiple Myeloma
AEterna Zentaris 135
Early research (Phase 1)Study completedNCT00060645
What this trial is testing

Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)

Who this might be right for
TumorsLymphomaMultiple Myeloma
Merck Sharp & Dohme LLC 33
Early research (Phase 1)Looking for participantsNCT06153251
What this trial is testing

Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Relapsed and/or Refractory Multiple Myeloma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company 187
Testing effectiveness (Phase 2)Study completedNCT00448201
What this trial is testing

Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaLymphoma+2 more
UNC Lineberger Comprehensive Cancer Center 71
Load More Results